Efgartigimod alfa
Based on 1 Customer Validation
Efgartigimod alfa (ARGX-113) is a reversibility, humanized Fc receptor antagonist . Efgartigimod alfa is a anti FcRn monoclonal immunoglobulin G (IgG1) Fc fragment. Efgartigimod reduces serum levels of total IgG, including pathogenic autoantibodies, by blocking FcRn function without permanent impairment. Efgartigimod alfa can be used for generalised myasthenia gravis (gMG) and primary immune thrombocytopenia research.
For research use only. We do not sell to patients.
- Purity: 98.48%
- CAS No.: 1821402-21-4
- Molecular Weight:51.28 kDa
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Human
FCGRT
Efgartigimod alfa (i.v.) rapidly and specifically reduces serum IgG levels in cynomolgus monkeys[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
FC-GAMMA-1
ELISA, FACS, Functional assay
-
Immobilized FCGRT Protein, Human (GST, HY-P72192) can bind Efgartigimod alfa. The EC50 for this effect is 535.9 ng/mL. -
Flow cytometric analysis of 1X106 THP-1 cells with Efgartigimod alfa (HY-147305, red). Cells were fixed with 4% paraformaldehyde. Then stained with the primary antibody at 1/200 dilution for an hour at 4℃. Alexa Fluor 488-conjugated AffiniPure Goat Anti-Human IgG H&L (AF488) (HY-P83776) was used as the secondary antibody at 1/1,000 dilution for 30 minutes at 4℃. cells without incubation with primary antibody were used as the unlabeled control (black).
Chemical Information
-
CAS No. 1821402-21-4
-
Appearance Liquid
-
Molecular Weight 51.28 kDa
-
Color Colorless to light yellow
-
SMILES
[Efgartigimod alfa]
-
Synonyms
ARGX-113
-
Shipping
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
-
Data Sheet (257 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
References
[1]. Heo YA. Efgartigimod: First Approval. Drugs. 2022 Feb;82(3):341-348. [Content Brief]
[2]. Heo YA. Efgartigimod Alfa in Generalised Myasthenia Gravis: A Profile of Its Use. CNS Drugs. 2023 May;37(5):467-473. [Content Brief]
[3]. Mansour GK, et al. Efgartigimod for Generalized Myasthenia Gravis and Beyond: A Narrative Review of Its Pharmacological Profile, Clinical Utility, and Expanding Applications. Biomedicines. 2025 Dec 4;13(12):2975. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)